Aerogen, an Ireland-based global leader in acute-care aerosol drug delivery, and Indian Association of Respiratory Care (IARC) have signed a Memorandum of Understanding (MoU) to enhance respiratory therapy education and improve patient care across India.

This strategic collaboration marks an important day in the development of respiratory care and highlights a shared commitment to elevate respiratory services and outcomes for patients nationwide.

The IARC, representing over 500 Respiratory Therapists, provides education and critical care updates both in India and abroad. With a robust advisory board of leading medical experts, IARC supports respiratory care across hospitals, home care, and training programmes.

On the other hand, Aerogen prioritises research and development to innovate its product range and set new standards for quality and efficiency in aerosol drug delivery technology.

This partnership combines Aerogen’s expertise with IARC’s network, focusing on education and training programmes to upskill respiratory therapists for the evolving needs of critical care in India.

It will leverage Aerogen’s advanced drug delivery systems to ensure higher-quality care in critical settings, improving patient outcomes and respiratory care services across various healthcare facilities in India.

Besides training, the collaboration also aims to increase awareness of aerosol and respiratory therapies among healthcare professionals and students, contributing to an improved standard of respiratory care across the country. 

Aerogen entered the Indian market in 2019 with the support of Enterprise Ireland, the Irish government organization responsible for promoting Irish enterprises globally.